Aims: Familial hypercholesterolemia (FH) is characterized by increased cardiovascular risk; despite high intensity statins, only a few of FH patients achieve the recommended low-density lipoprotein cholesterol (LDL-C) targets. Our aim was to evaluate the efficacy of six-month add-on therapy with proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9-i) on lipid profile and pulse wave velocity (PWV) in FH patients. Methods: We enrolled 53 genetically confirmed FH patients with an LDL-C off-target despite high-intensity statins and ezetimibe. For all patients, we performed biochemical analysis and PWV evaluation at baseline (T0) and after six months (T1) of optimized treatment. Results: After 6-month add-on therapy, patients achieved both a significant LDL-C and PWV reduction. In a linear regression analysis we showed a beta index of 0.334 for the relationship between ∆PWV and ∆LDL (p< 0.05). Conclusion: The addition of PCSK9-i on high intensity statin therapy significantly improved lipid and PWV profile in FH patients; moreover, ΔPWV was associated with ΔLDL. Our study confirmed additional beneficial role of these novel therapies in FH subjects

EFFICACIA DEL TRATTAMENTO CON ANTICORPI MONOCLONALI ANTI-PCSK9 SU PROFILO LIPIDICO ED INDICI DI RIGIDITA' VASCOLARE IN PAZIENTI FH

ARAGONA, CATERINA ORIANA
2019-11-07

Abstract

Aims: Familial hypercholesterolemia (FH) is characterized by increased cardiovascular risk; despite high intensity statins, only a few of FH patients achieve the recommended low-density lipoprotein cholesterol (LDL-C) targets. Our aim was to evaluate the efficacy of six-month add-on therapy with proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9-i) on lipid profile and pulse wave velocity (PWV) in FH patients. Methods: We enrolled 53 genetically confirmed FH patients with an LDL-C off-target despite high-intensity statins and ezetimibe. For all patients, we performed biochemical analysis and PWV evaluation at baseline (T0) and after six months (T1) of optimized treatment. Results: After 6-month add-on therapy, patients achieved both a significant LDL-C and PWV reduction. In a linear regression analysis we showed a beta index of 0.334 for the relationship between ∆PWV and ∆LDL (p< 0.05). Conclusion: The addition of PCSK9-i on high intensity statin therapy significantly improved lipid and PWV profile in FH patients; moreover, ΔPWV was associated with ΔLDL. Our study confirmed additional beneficial role of these novel therapies in FH subjects
7-nov-2019
File in questo prodotto:
File Dimensione Formato  
Tesi dottorato_Aragona_definitiva.pdf

accesso aperto

Descrizione: Tesi di dottorato
Tipologia: Documento in Post-print (versione successiva alla peer review e accettata per la pubblicazione)
Licenza: Creative commons
Dimensione 415.12 kB
Formato Adobe PDF
415.12 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11570/3144291
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact